Table 2.
Clinical characteristics of ovarian cancer between early stage and advanced stage
| Variable | Early stage (n= 85) | Advanced stage (n=140) | X2 | P value | ||
|---|---|---|---|---|---|---|
| n (%) | Middle (Rang) | n (%) | Middle (Rang) | |||
| Age (years) | 0.414 | 0.520 | ||||
| <50 | 43 (50.6) | 43 (18~49) | 77 (55.0) | 43 (23~49) | ||
| ≥50 | 42 (49.4) | 58 (50~89) | 63 (45.0) | 60 (50~80) | ||
| BMI (kg/m2) | 4.703 | 0.03 | ||||
| <24 | 39 (45.9) | 20.96 (17.1~23.8) | 85 (60.7) | 25.6 (24.0~29.8) | ||
| ≥24 | 46 (65.1) | 24.79 (24.0~29.8) | 55 (39.3) | 20.9 (16.5~23.8) | ||
| Histologic subtype, n (%) | ||||||
| Serous | 43 (50.6) | 108 (77.1) | 16.897 | <0.001 | ||
| Non-serous | 42 (49.4) | 34 (22.9) | ||||
| Histological grade, n (%) | ||||||
| G1 | 59 (69.4) | 123 (54.7) | 16.897 | 0.001 | ||
| G2/G3 | 26 (30.6) | 17 (45.3) | ||||
| Malignant ascites, n (%) | 51.533 | <0.001 | ||||
| Yes | 25 (29.4) | 109 (77.9) | ||||
| No | 60 (70.6) | 31 (22.1) | ||||
| Lymph node metastases, n (%) | 40.497 | <0.001 | ||||
| Yes | 10 (11.8) | 76 (33.8) | ||||
| No | 75 (88.2) | 31 (66.2) | ||||
| White blood cell*109 | 0.213 | 0.644 | ||||
| <6.40 | 28 | 5.5 (3.6~6.4) | 42 (60.7) | 5.35 (3.3~6.4) | ||
| ≥6.40 | 57 | 7.7 (6.4~16.5) | 98 (39.3) | 8.63 (6.4~16.2) | ||
| LMR | 36.470 | <0.001 | ||||
| ≤3.7 | 25 (11.8) | 2.43 (0.9~3.6) | 99 (33.8) | 2.15 (0.5~3.7) | ||
| >3.7 | 60 (88.2) | 4.93 (3.7~18.0) | 41 (66.2) | 4.93 (3.7~11.6) | ||
| Serum CA125 (U/mL) | 39.13 | <0.001 | ||||
| ≤95.7 | 52 | 34.65 (2.2~95.7) | 28 | 22.4 (1.8~74.7) | ||
| >95.7 | 33 | 342.5 (98~1401) | 112 | 423.5 (95.8~5672.6) | ||
BMI, body mass index; LMR, lymphocyte/monocyte ratio; CA125, cancer antigen 125.